A Placebo-Controlled Phase II Study of Ruxolitinib in Combination With Pemetrexed and Cisplatin for First-Line Treatment of Patients With Advanced Nonsquamous Non–Small-Cell Lung Cancer and Systemic Inflammation
- Resource Type
- Article
- Source
- In
Clinical Lung Cancer September 2018 19(5):e567-e574 - Subject
- Language
- ISSN
- 1525-7304